13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Automated segmentation of medial temporal lobe subregions on in vivo T1‐weighted MRI in early stages of Alzheimer's disease

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Medial temporal lobe (MTL) substructures are the earliest regions affected by neurofibrillary tangle pathology—and thus are promising biomarkers for Alzheimer's disease (AD). However, automatic segmentation of the MTL using only T1‐weighted (T1w) magnetic resonance imaging (MRI) is challenging due to the large anatomical variability of the MTL cortex and the confound of the dura mater, which is commonly segmented as gray matter by state‐of‐the‐art algorithms because they have similar intensity in T1w MRI. To address these challenges, we developed a novel atlas set, consisting of 15 cognitively normal older adults and 14 patients with mild cognitive impairment with a label explicitly assigned to the dura, that can be used by the multiatlas automated pipeline (Automatic Segmentation of Hippocampal Subfields [ASHS‐T1]) for the segmentation of MTL subregions, including anterior/posterior hippocampus, entorhinal cortex (ERC), Brodmann areas (BA) 35 and 36, and parahippocampal cortex on T1w MRI. Cross‐validation experiments indicated good segmentation accuracy of ASHS‐T1 and that the dura can be reliably separated from the cortex (6.5% mislabeled as gray matter). Conversely, FreeSurfer segmented majority of the dura mater (62.4%) as gray matter and the degree of dura mislabeling decreased with increasing disease severity. To evaluate its clinical utility, we applied the pipeline to T1w images of 663 ADNI subjects and significant volume/thickness loss is observed in BA35, ERC, and posterior hippocampus in early prodromal AD and all subregions at later stages. As such, the publicly available new atlas and ASHS‐T1 could have important utility in the early diagnosis and monitoring of AD and enhancing brain‐behavior studies of these regions.

          Related collections

          Author and article information

          Contributors
          long.xie@uphs.upenn.edu
          Journal
          Hum Brain Mapp
          Hum Brain Mapp
          10.1002/(ISSN)1097-0193
          HBM
          Human Brain Mapping
          John Wiley & Sons, Inc. (Hoboken, USA )
          1065-9471
          1097-0193
          29 April 2019
          15 August 2019
          : 40
          : 12 ( doiID: 10.1002/hbm.v40.12 )
          : 3431-3451
          Affiliations
          [ 1 ] Penn Image Computing and Science Laboratory (PICSL), Department of Radiology University of Pennsylvania Philadelphia Pennsylvania
          [ 2 ] Department of Radiology University of Pennsylvania Philadelphia Pennsylvania
          [ 3 ] Penn Memory Center University of Pennsylvania Philadelphia Pennsylvania
          [ 4 ] Department of Neurology University of Pennsylvania Philadelphia Pennsylvania
          [ 5 ] Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (ITACA) Universidad Politécnica de Valencia Valencia Spain
          [ 6 ] IBM Almaden Research Center San Jose California
          [ 7 ] Allen Institute for Brain Science Seattle Washington
          [ 8 ] Institute of Neuroscience, School of Basic Medical Sciences Guangzhou Medical University Guangzhou People's Republic of China
          Author notes
          [*] [* ] Correspondence

          Long Xie, Penn Image Computing and Science Laboratory (PICSL), 3700 Hamiton Walk, Richards building 6 floor, Philadelphia, PA 19104.

          Email: long.xie@ 123456uphs.upenn.edu

          Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ( http://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

          Author information
          https://orcid.org/0000-0002-7184-7028
          Article
          PMC6697377 PMC6697377 6697377 HBM24607
          10.1002/hbm.24607
          6697377
          31034738
          4477f854-10bc-4725-9216-57e634a296cf
          © 2019 Wiley Periodicals, Inc.
          History
          : 16 March 2019
          : 15 April 2019
          Page count
          Figures: 4, Tables: 6, Pages: 21, Words: 16980
          Funding
          Funded by: Northern California Institute for Research and Education , open-funder-registry 10.13039/100009804;
          Funded by: Foundation for the National Institutes of Health , open-funder-registry 10.13039/100000009;
          Funded by: Canadian Institutes of Health Research , open-funder-registry 10.13039/501100000024;
          Funded by: Transition Therapeutics
          Funded by: Takeda Pharmaceutical Company , open-funder-registry 10.13039/100008373;
          Funded by: Servier , open-funder-registry 10.13039/501100011725;
          Funded by: Piramal Imaging
          Funded by: Pfizer Inc. , open-funder-registry 10.13039/100004319;
          Funded by: Novartis Pharmaceuticals Corporation , open-funder-registry 10.13039/100008272;
          Funded by: Neurotrack Technologies
          Funded by: NeuroRx Research
          Funded by: Meso Scale Diagnostics, LLC. , open-funder-registry 10.13039/100007054;
          Funded by: Lundbeck and Merck & Co., Inc.
          Funded by: Lumosity
          Funded by: Johnson & Johnson Pharmaceutical Research & Development LLC.
          Funded by: Janssen Alzheimer Immunotherapy Research & Development, LLC.
          Funded by: IXICO Ltd.
          Funded by: GE Healthcare , open-funder-registry 10.13039/100006775;
          Funded by: Fujirebio , open-funder-registry 10.13039/501100005062;
          Funded by: Genentech, Inc. , open-funder-registry 10.13039/100004328;
          Funded by: F. Hoffmann‐La Roche Ltd. , open-funder-registry 10.13039/100007013;
          Funded by: EuroImmun
          Funded by: Eli Lilly and Company , open-funder-registry 10.13039/100004312;
          Funded by: Elan Pharmaceuticals, Inc.
          Funded by: Cogstate and Eisai Inc.
          Funded by: CereSpir, Inc.
          Funded by: Bristol‐Myers Squibb Company , open-funder-registry 10.13039/100002491;
          Funded by: Biogen , open-funder-registry 10.13039/100005614;
          Funded by: BioClinica, Inc. , open-funder-registry 10.13039/100007742;
          Funded by: Araclon Biotech
          Funded by: Alzheimer's Drug Discovery Foundation , open-funder-registry 10.13039/100002565;
          Funded by: Alzheimer's Association , open-funder-registry 10.13039/100000957;
          Funded by: AbbVie , open-funder-registry 10.13039/100006483;
          Funded by: National Institute of Biomedical Imaging and Bioengineering , open-funder-registry 10.13039/100000070;
          Funded by: National Institute on Aging , open-funder-registry 10.13039/100000049;
          Funded by: Department of Defense ADNI
          Award ID: W81XWH‐12‐2‐0012
          Funded by: Alzheimer's Disease Neuroimaging Initiative , open-funder-registry 10.13039/100007333;
          Award ID: U01 AG024904
          Funded by: Spain Ministry of Economy, Industry and Competitiveness
          Award ID: DPI2017‐87743‐R
          Funded by: Foundation Philippe Chatrier
          Funded by: BrightFocus Foundation , open-funder-registry 10.13039/100006312;
          Funded by: National Institutes of Health , open-funder-registry 10.13039/100000002;
          Award ID: R01‐AG055005
          Award ID: R01‐EB017255
          Award ID: P30‐AG010124
          Award ID: R01‐AG040271
          Award ID: R01‐AG056014
          Categories
          Research Article
          Research Articles
          Custom metadata
          2.0
          August 15, 2019
          Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.2 mode:remove_FC converted:15.11.2019

          mild cognitive impairment,segmentation,T1‐weighted magnetic resonance imaging,anterior and posterior hippocampus,biomarker,Alzheimer's disease,dura mater,transentorhinal cortex,perirhinal cortex,entorhinal cortex

          Comments

          Comment on this article